Aclarubicin: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "__NOTOC__ {{SI}} {{CMG}} {{SK}} Aclacinomycin A ==Overview== Aclarubicin is an anthracycline drug <ref name="pmid1655244">{{cite journal| author=Jensen PB, Jensen PS, Demant...")
 
No edit summary
Line 1: Line 1:
__NOTOC__
{{Drugbox
{{SI}}
| Verifiedfields = changed
{{CMG}}
| Watchedfields = changed
| verifiedrevid = 477240878
| IUPAC_name = (1''S'',2''S'',4''R'')-Methyl 4-(((2''S'',5''R'',6''R'')-4-(dimethylamino)-5-(((1''S'',3''R'',4''S'')-3-hydroxy-5-methyl-4-(((2''S'',6''R'')-6-methyl-5-oxotetrahydro-2''H''-pyran-2-yl)oxy)cyclohexyl)oxy)-6-methyltetrahydro-2''H''-pyran-2-yl)oxy)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate
| image = Aclarubicin.svg


{{SK}} Aclacinomycin A
<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|international|aclarubicin}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Rx-only
| routes_of_administration = [[Intravenous therapy|IV]]


==Overview==
<!--Pharmacokinetic data-->
Aclarubicin is an anthracycline drug <ref name="pmid1655244">{{cite journal| author=Jensen PB, Jensen PS, Demant EJ, Friche E, Sørensen BS, Sehested M et al.| title=Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. | journal=Cancer Res | year= 1991 | volume= 51 | issue= 19 | pages= 5093-9 | pmid=1655244 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1655244 }} </ref> that is used in the treatment of cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin.
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 57576-44-0
| ATC_prefix = L01
| ATC_suffix = DB04
| ATC_supplemental = 
| PubChem = 42474
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 1931
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 74KXF8I502
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02756
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 74619
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1697719
 
<!--Chemical data-->
| C=42 | H=53 | N=1 | O=15
| molecular_weight = 811.86 g/mol
| smiles = CCC1(CC(C2=C(C1C(=O)OC)C=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4O)OC5CC(C(C(O5)C)OC6CC(C(C(O6)C)OC7CCC(=O)C(O7)C)O)N(C)C)O
| InChI = 1/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3
| InChIKey = USZYSDMBJDPRIF-UHFFFAOYAH
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = USZYSDMBJDPRIF-UHFFFAOYSA-N
}}
 
'''Aclarubicin''' ([[International Nonproprietary Name|INN]]) or '''aclacinomycin A'''<ref name="pubchem">{{PubChem|451415}}</ref> is an [[anthracycline]] drug<ref name="pmid1655244">{{cite journal |author=Jensen PB, Jensen PS, Demant EJ, ''et al.'' |title=Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II |journal=Cancer Res. |volume=51 |issue=19 |pages=5093–9 |date=October 1991 |pmid=1655244 |doi= |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=1655244}}</ref> that is used in the treatment of [[cancer]]. Soil bacteria ''[[Streptomyces galilaeus]]'' can produce aclarubicin.


==References==
==References==
{{Reflist|2}}
{{reflist}}
 
{{Chemotherapeutic agents}}
 
[[Category:Anthracyclines]]
[[Category:Topoisomerase inhibitors]]


{{WH}}
{{WS}}


[[Category:Needs content]]
{{antineoplastic-drug-stub}}

Revision as of 17:37, 6 April 2015

Aclarubicin
File:Aclarubicin.svg
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		IV
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC42H53NO15
Molar mass811.86 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Aclarubicin (INN) or aclacinomycin A[1] is an anthracycline drug[2] that is used in the treatment of cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin.

References

  1. ↑ Template:PubChem
  2. ↑ Jensen PB, Jensen PS, Demant EJ; et al. (October 1991). "Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II". Cancer Res. 51 (19): 5093–9. PMID 1655244.


Template:Antineoplastic-drug-stub

Retrieved from "https://www.wikidoc.org/index.php?title=Aclarubicin&oldid=1083307"